



**Joanna Horobin, M.B., Ch.B.**

Chief Medical Officer

Verastem

Dr. Horobin has 30 years of pharmaceutical drug development experience. As President of Syndax Pharmaceuticals Dr. Horobin designed and implemented the phase 2 clinical development of Entinostat in metastatic breast and lung cancer. Formerly VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY), COO of CombinatoRx (NASDAQ: CRXX, now ZLCS) and EVP at EntreMed with experience spanning clinical development, marketing, and general management in both public and private companies. Dr. Horobin was VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY) where she led the global oncology business, including the successful global launch of Taxotere<sup>®</sup> (docetaxel) in breast cancer and Campto/Camptosar<sup>®</sup> (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte<sup>®</sup> (lenograstim). Previously, Dr. Horobin played significant leadership roles in the approvals of Lovenox<sup>®</sup>, Celectol<sup>®</sup>, Augmentin<sup>®</sup>, Timentin<sup>®</sup>, temocillin, Bactroban<sup>®</sup> and Relafen<sup>®</sup>/Reliflex<sup>®</sup>. Dr. Horobin received her medical degree from the University of Manchester, England. While in clinical practice she gained membership to the Royal College of General Practitioners in the United Kingdom and holds a diploma of pharmaceutical medicine from the Royal College of Physicians in the United Kingdom.